Evry, Monday, April 15, 2013 – IntegraGen, today announced its financial results for the fiscal year ending December 31, 2102. The accounts were examined during the meeting of the Board of Directors held on April 11, 2013.
Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic
IntegraGen’s vocation is firstly to establish the link between innovations derived from molecular research and medical practise, by developing biomarkers for autism and oncology specifically intended for clinical use, and subsequently to make its genomics services available to practitioners and researchers thanks to its exceptional technological and scientific know-how.
With the support of its network of partners and experts, IntegraGen is now well established as one of the leaders in its sector.